NSE: LAURUSLABS | BSE: 540222

Expensive Star

Download real time

1787.30 -64.40 (-3.48%)

New 52W High in past week

1.6M NSE+BSE Volume

NSE 14 Aug, 2026 3:31 PM (IST)

96,570

Market Cap

High in industry

Beta 1Year

Low volatility

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Search Inside the pdf :

Laurus Labs Ltd.

27 Jul 2026

1787.30

-3.48%

Outlook

Accumulate: Laurus Labs Ltd.

Target

Deven Choksey

We expect Laurus Labs to sustain its growth momentum, led by continued strength in the CDMO business as more late-stage molecules transition into commercial manufacturing.

Laurus Labs Ltd. has an average target of 1715.00 from 4 brokers.

Laurus Labs Ltd.

26 Jul 2026

1787.30

-3.48%

CDMO influence keeps growing- in numbers and aspirations : Laurus Labs operates in the segment of generic APIs & FDFs (formulations), custom synthesis (CDMO) and biotechnology. Major focus in APIs is...

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

24 Jul 2026

1787.30

-3.48%

Laurus Labs Ltd.– Q1FY27 Preview

Accumulate: Laurus Labs Ltd.

Target

Deven Choksey

We expect revenue to grow 15.0% YoY to INR 18,045 Mn, driven by continued momentum in the CDMO and Finished Dosages (FDF) businesses.

Number of FII/FPI investors increased from 429 to 509 in Jun 2026 qtr.

Laurus Labs Ltd.

24 Jul 2026

1787.30

-3.48%

A blockbuster beat led by CDMO momentum

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (Laurus) delivered yet another outstanding quarter with a 14%/31%/53% beat on revenue/EBITDA/PAT. The performance was driven by the CDMO and formulation (FDF) segment.

Laurus Labs has gained 76.86% in the last 6 Months

Laurus Labs Ltd.

07 May 2026

1787.30

-3.48%

Strong FY26 Driven by CDMO and Margin Expansion

Accumulate: Laurus Labs Ltd.

Recommendation Target

Deven Choksey

The company’s growth is structurally dependent upon the CDMO segment which is margin accretive one. The company is building its internal strengths through expanding its capabilities and focusing upon high margin products.

Deven Choksey increased Accumulate price target of Laurus Labs Ltd. to 1830.0 on 27 Jul, 2026.

Laurus Labs Ltd.

03 May 2026

1787.30

-3.48%

Laurus Labs (HOLD): A long runway for CDMO expansion

Hold: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were -2.5%/2.7%/4.3% above our estimates. EBITDA Margin was reported 144 bps above our estimates

Laurus Labs has gained 107.07% in the last 1 Year

Laurus Labs Ltd.

30 Apr 2026

1787.30

-3.48%

CDMO, API segments boost earnings

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab delivered in-line revenue in 4QFY26. Improved operating leverage led to a 7% beat on EBITDA. A lower-than-expected tax rate led to 19% beat on PAT for the quarter.

Deven Choksey increased Accumulate price target of Laurus Labs Ltd. to 1830.0 on 27 Jul, 2026.

Laurus Labs Ltd.

19 Mar 2026

1787.30

-3.48%

Building future-ready CDMO powerhouse

Buy: Laurus Labs Ltd.

Motilal Oswal

Laurus is witnessing a strong scale-up in CDMO business from global innovator pharma, including rare formulation-level contracts for patented products (beyond API/intermediates).

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

25 Feb 2026

1787.30

-3.48%

Positioned to capitalize on CDMO’s commercial ramp-up cycle

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

We analyzed narration versus actual outcomes and financial performance across CDMO peers, highlighting an uneven recovery, with some companies facing guidance resets due to program delays, destocking, and slower commercial conversions.

Laurus Labs Ltd. has an average target of 1715.00 from 4 brokers.

Is Laurus Labs Ltd. worth buying?

1257 Votes:

Buy 79.71%

Sell 10.82%

Hold 9.47%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf